Isoray Announces Second Quarter Fiscal 2021 Financial Results

Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year   RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

Isoray Announces Pricing of $45 Million Public Offering

RICHLAND, Wash., February 4, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of...

Isoray Announces Proposed Underwritten Public Offering

RICHLAND, Wash., February 3, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer...

Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference

RICHLAND, WASHINGTON – January 7, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...